Serotonin1A receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 4, 2008, Pages 411-420

  Batool, Farhat ^a   Haleem, Darakhshan J ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

5 HT syndrome; 5 HT1A receptors; 8 OH DPAT; EPS; Haloperidol; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PRESYNAPTIC RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; EXTRAPYRAMIDAL SYNDROME; LOCOMOTION; MALE; METABOLISM; RAT; SEROTONIN SYNDROME; TIME; UPREGULATION; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; HALOPERIDOL; LOCOMOTION; MALE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; RECEPTORS, PRESYNAPTIC; SEROTONIN AGONISTS; SEROTONIN SYNDROME; TIME FACTORS; UP-REGULATION;

EID: 58149265732     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Alhenius S, Hillegart V and Wijksrtrom A (1989). Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat. Naunyn- Schmiedeberg's Archives of Pharmacology, 339(5): 551-556.
2. Backus LI, Sharp T and Grahame-Smith DG (1990). Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br. J. Pharmacol., 100(4): 793-799.
3. Balsara JJ, Jadhav JH, Muley MP and Chanderkew AG (1979). Effects of drugs influencing central serotonin mechanism on metamphetamine-induced stereotypic behavior in the rat. Psychopharmacology, 64: 303-307.
4. Baldessarini RJ (1985). Clinical and epidemiologic aspects of tardive dyskinesia. J. Clin. Psychiatry., 46(4 Pt 2): 8-13.
5. Bantick RA, Rabiver EA, Hirani E, deVries MH, Hume SP and Grasby PM (2004). Occupancy of agonist drugs at the 5-HT1A receptors. Neuropsychopharmacology, 29: 847-859.
6. Bardin L, Auclair A, Kleven MS, Prinssen EPM, Koek W, Newman-Tancredi A and Depoortere R (2007). Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural Pharmacology, 8(2): 103-118.
7. Batool F, Siddiqui S and Haleem DJ (2001). Neurochemical and behavioral profiles of 1-(1- naphthyl) piperazine in rats. JCPSP, 11(1): 50-56.
8. Batool F, Saify ZS, Haleem MA and Haleem DJ (2000). Neurochemical and extrapyramidal effects of atypical neuroleptic clozapine in rats. Pak. J. Pharmac. Sci., 13(1): 47-55.
9. Bishnoi M. Kumar A, Chopra K and Kulkarni SK (2007). Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Indian J. Exp. Biol., 45(2): 175-179.
10. Casey DE (1991). Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research, 4(2): 109-120.
11. Casey DE (1993). Serotonergic and dopaminergic effects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology, 12: S55- S59.
12. Casey DE (1994). Motor and mental aspects of acute extrapyramidal syndromes. Acta. Psychiatr. Scand. Suppl., 380: 14-20.
13. Christofferson CL and Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropharmacology, 18: 399-402.
14. Creese I, Burt D and Snyder S (1977). Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science, 197(4303): 596-598.
15. Dixon LB, Lehman AF and Levine J (1995). Conventional antipsychotic medications for schizophrenia. Schizophr. Bull., 21(4): 567-577.
16. Ellenbroek BA, Artz MT and Cools AR (1991). The involvement of dopamine D1 and D2 receptors in the effects of classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmacol., 196: 103-108.
17. Ensler K, Ryan CN and Evenden JL (1993). Effects of repeated treatment with 5-HT1A agonists on active avoidance responding in the rat. Psychopharmacology, 12(1): 45-54.
18. Goodwin GM and Green AR (1985). A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br. J. Pharmacol., 84: 743-753.
19. Haleem DJ, Saify ZS, Siddiqui S, Batool F and Haleem MA (2002a). Pre and postsynaptic responses to 1-(1- naphthylpiperazine) following adaptation to stress in rats. Prog. Neuropsychopharmncol. Biol. Psychiatry, 26: 149-156.
20. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS and Haleem MA (2002b). Differences in the effects of haloperidol and clozapine on rat brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med. Sci Monit., 8(9): BR354-BR361.
21. Haleem DJ and Khan NH (2003). Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry., 27(4): 645-651.
22. Haleem DJ, Shireen E and Haleem MA (2004). Somatodendritic and postsynaptic 5-HT1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry., 28: 1323-1329.
23. Haleem DJ, Samad N and Haleem MA (2007). Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. Bahvioural Pharmacology, 18(2): 147-153.
24. Hicks PB (1990). The effects of serotonergic agents on haloperidol-induced catalepsy. Life Sci., 47: 1609-1615.
25. Hinds RE, Kilpatrick IC (1994). Stimulation of 5-HT1A receptors prevents haloperidol-induced catalepsy without influencing the concurrently enhanced dopamine utilization in the rat brain. Br J Pharmacol., 111: 11P.
26. Huber G and Gross G (1997). Advances in therapy and prevention of schizophrenic disorders. Neurol. Psychiat. Brain Res., 5: 1-8.
27. Huber G and Gross G (1999). Conventional and newer neuroleptics in the treatment of schizophrenia spectrum disorders. Neurol. Psychiat. Brain Res., 7: 15-26.
28. Intitute of Lab Animal Resources (1996). Ethical committee guideline, NRC.
29. Ishikane T, Kusumi I, Matsubara R, Matsubara S and Koyama T (1997). Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol., 321(2): 163-9.
30. Ishikawa J and Meltzer HY (1999). R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)- sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther., 291(3): 1227-32.
31. Invernizzi RW, Cervo L and Samanin R (1988). 8-OHDPAT, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology, May 27(5): 515-518.
32. Kane JM and Marder SR (1993). Psychopharmacology treatment of schizophrenia. Schizophrenia Bull., 19(2): 287-302.
33. Kane JM (1996). Schizophrenia. New Engl. J. Med., 334: 34-41.
34. Kleven M, Prinssen EP and Koek W (1996). Role of 5- HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur. J. Pharmacol., 313(1-2): 25-34.
35. Kapur S and Ramington G (1996). Serotonin dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry., 153: 466-476.
36. Kuroki T, Ichikawa J, Dai J and Meltzer HY (1996). R(+)- 8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res., 743(1-2): 357-61.
37. Lucas G and Bonhomme N (1997). 8-OH-DPAT, a 5-HT- 1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal DA release. Psychopharmacology, 131: 57-63.
38. Meltzer HY, Li Z, Kaneda Y and Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat Schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 27: 1159-1172.
39. Millan MJ, Dekeyne A and Gobert A (1998). Serotonin (5-HT-2C) receptors tonically inhibit dopamine (DA) and Noradrenaline (NA), but not 5-HT release in the frontal cortex. Neuropsychopharmacology, 37: 953-955.
40. Millan MJ (2000). Improving the treatment of schizophrenia: focus on serotonin (5HT1A) receptors. J. Pharmacol. & Exp. Therap., 295(3): 853-861.
41. Miyamoto S, Duncan GE, Marx CE and Liberman JA (2005). Treatment for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mole. Psychiatry., 10: 79-104.
42. Needham PL, Skill MJ, Kettle M and Heal DJ (1994). Attenuation of catalepsy by the 5-HT1A/5-HT7 agonist, 8-OH-DPAT, is mediated by postsynaptic receptors. Br. J. Pharmacol., 112: 491P.
43. Prinssen EPM, Koek W and Keleven MS (2000). Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5- HT1A receptors. Eur. J. Pharmacol., 395: 143-147.
44. Prinssen EP, Kleven MS and Koek W (1999). Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotics and extrapyramidal effects. Psychophramacol., 144(1): 20-29.
45. Samad N, Batool F and Haleem DJ (2007). Neurochemical and behavioral effects of 8-OH-DPAT following exposure to restraint stress in rats. Pharmacol. Rep., 59(2): 173-80.
46. Sandyk R and Fischer H (1988). Serotonin involuntary movement disorders. Int. J. Neurosci., 42: 185-205.
47. Smith LM and Peroutka SJ (1986). Differential effects of 5-Hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav., 24: 1513-1519.
48. Tricklebank MD, Forler C and Forzard JR (1984). The involvement of subtypes of 5-HT1 receptors and catecholaminergic receptors to 8-hydroxy-2-(di-npropylamino) tetraline in the rat. Eur. J. Pharmacol., 106: 271-282.
49. Vonvoigtlander PF, Losey EG and Trienzenberg HJ (1975). Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J. Pharmacol. Exp. Ther.,193: 88-94.
50. Wadenberg ML (1996). Serotonergic mechanism in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev., 20: 325-339.
51. Wadenberg ML, Soliman A, Vander-Spek SC and Kapur S (2001). Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology, 25(5): 633-641.
52. Yamada J. Sugimoto Y and Horisaka K (1988). The behavioral effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol., 154(3): 299-304.
53. Yamada J. Sugimoto Y and Horisaka K (1989). The evidence for the involvement of the 5-HT1A receptors in 5-HT syndrome induced in mice by tryptamine. Japan. J. Pharmacol., 51: 421-424.